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Background: Our aim was to assess clinical outcome after transcatheter aortic valve implantation (TAVI) performed with the two commercially 
available valves using three delivery approaches selected in a stepwise fashion.
Methods: We report 30-day and one year clinical outcomes of high risk patients consecutively treated in a single center with either the Medtronic-
CoreValve (MCV) or Edwards-SAPIEN valve (ESV) delivered via the trans-femoral or trans-axillary approaches and ESV via the trans-apical approach.
Results: A total of 213 patients underwent TAVI: 170 via trans-femoral (71 MCV and 99 ESV), 23 via trans-axillary (19 MCV and 4 ESV) and 18 via 
trans-apical approach. Following the trans-femoral approach, the procedural success rate was 95% and major vascular complication rate was 20%. 
No intra-procedural deaths occurred. Procedural success rate of trans-apical and trans-axillary approaches were 89% and 91% respectively. The 
30-day mortality rate was 2.4% in trans-femoral group, 11% in trans-apical and 4% in the trans-axillary access. Cumulative death rate at one year 
follow-up was 25% in trans-femoral, 41% in trans-apical, and 44% in trans-axillary groups. The adjusted multivariable analysis will be presented at 
time of presentation.
Conclusions:  Routine TAVI utilizing both MCV and ESV with a selection of approaches is feasible and allows treatment of a wide range of patients 
with good overall procedural success rates and 30-day outcomes. The high death rate at one year follow-up is consistent with other reports and 
reflects the baseline high risk of these patients
